Xeltis Steps Up Clinical Spotlight on aXess With Dual Kidney Disease Forum Push

Xeltis is drawing investor attention this week as it advances clinical visibility for aXess, its restorative vascular access conduit for hemodialysis. The company plans multiple high-profile presentations of 12‑month EU pivotal data, underscoring momentum in later-stage validation of its core technology.

At the Vascular Access Society of the Americas 2026 Vascular Access for Dialysis Symposium in Salt Lake City, Key Opinion Leader Dr. Jason K. Wagner is slated to present aXess data. His session will highlight 12‑month EU pivotal results and provide an update on the ongoing U.S. pivotal study, positioning the program squarely in the de-risking phase.

Xeltis’ CEO, CMO, and U.S. clinical affairs specialists are expected to attend the VASA meeting, signaling a coordinated push to engage vascular access experts and payers. Their presence may help shape clinician perceptions and support future adoption dynamics if aXess advances toward regulatory clearance.

In parallel, the company will present at the American Association of Kidney Patients Annual Global Summit on Kidney Disease Innovations, a major patient-led virtual event. Xeltis’ VP of U.S. Clinical Affairs, Shawn M. Gage, will join a vascular access innovation session focused on the aXess device and its 12‑month EU pivotal data.

Participation in this patient-focused summit is designed to build credibility with clinicians, patients, and advocacy groups in the kidney disease ecosystem. The company is promoting free registration to the session, indicating an effort to broaden awareness across the nephrology and dialysis communities.

While detailed quantitative efficacy and safety results, timelines, and regulatory milestones are not disclosed, the consistent emphasis on pivotal data signals advancing clinical maturity. If positive, these results could lay groundwork for regulatory engagement and eventual commercialization in the hemodialysis vascular access market.

Strategically, Xeltis is clearly concentrating on the hemodialysis vascular access niche, a segment characterized by recurring procedures and significant healthcare costs. By targeting specialized conferences and patient-led forums, the company appears to be positioning aXess as a potentially differentiated solution ahead of key approval and adoption inflection points.

Overall, the week reflects a communication-driven milestone for Xeltis, with aXess moving further into the spotlight through targeted clinical and patient community outreach. Investors will now look for more granular clinical data and clearer regulatory pathways to assess the long-term impact on the company’s growth prospects.